Study Subject Participation Status Clinical Trial adalimumab
Item
participation in the prior adalimumab study
boolean
C2348568 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C1122087 (UMLS CUI [1,3])
Body Weight
Item
body weight less than 100 kg.
boolean
C0005910 (UMLS CUI [1])
Investigational New Drug Administration Continue
Item
subject's who wished to continue the study drug administration
boolean
C0013230 (UMLS CUI [1,1])
C1533734 (UMLS CUI [1,2])
C0549178 (UMLS CUI [1,3])
Gender Postmenopausal state | Female Sterilization | Gender Contraceptive methods
Item
females must be postmenopausal for at least 1 year, surgically sterile, or practicing birth control throughout the study and for 90 days after study completion.
boolean
C0079399 (UMLS CUI [1,1])
C0232970 (UMLS CUI [1,2])
C0015787 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Clinical Trial adalimumab subcutaneous
Item
a subject who experienced any of the following during the prior adalimumab sc dosing study:
boolean
C0008976 (UMLS CUI [1,1])
C1122087 (UMLS CUI [1,2])
C1522438 (UMLS CUI [1,3])
Diabetes Mellitus Advanced | Diabetes mellitus poor control
Item
advanced or poorly controlled diabetes
boolean
C0011849 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0860161 (UMLS CUI [2])
Medical condition Poorly controlled
Item
any poorly controlled medical condition
boolean
C3843040 (UMLS CUI [1,1])
C3853134 (UMLS CUI [1,2])
intraarticular injection of corticosteroids | Adrenal Cortex Hormones Intramuscular | Adrenal Cortex Hormones Intravenous
Item
intra-articular, intramuscular or iv administration of corticosteroids
boolean
C2064783 (UMLS CUI [1])
C0001617 (UMLS CUI [2,1])
C1556154 (UMLS CUI [2,2])
C0001617 (UMLS CUI [3,1])
C1522726 (UMLS CUI [3,2])
Operation on joint
Item
joint surgery.
boolean
C0185132 (UMLS CUI [1])
Pharmaceutical Preparations Excluded prescribed
Item
a subject who has been prescribed excluded medications during previous adalimumab study.
boolean
C0013227 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
C0278329 (UMLS CUI [1,3])
Substance Use Disorders Clinical Significance | Intravenous Drug Abuse | Listeriosis | Tuberculosis | Lymphoma | leukemia | Malignant Neoplasms | Basal cell carcinoma Treated Successful
Item
history of clinically significant drug or alcohol abuse, intravenous (iv) drug abuse, active infection with listeria or tuberculosis (tb), lymphoma, leukemia, or any malignancy with the exception of successfully treated non- metastatic basal cell carcinoma of the skin.
boolean
C0038586 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0086181 (UMLS CUI [2])
C0023860 (UMLS CUI [3])
C0041296 (UMLS CUI [4])
C0024299 (UMLS CUI [5])
C0023418 (UMLS CUI [6])
C0006826 (UMLS CUI [7])
C0007117 (UMLS CUI [8,1])
C1522326 (UMLS CUI [8,2])
C1272703 (UMLS CUI [8,3])
Chronic infectious disease | Communicable Disease | Communicable Disease Episode Major | Hospitalization Required | Antibiotics Intravenous Patient need for | Antibiotics Oral chronic
Item
a subject who experienced chronic or active infection or any major episode of infection requiring hospitalization or treatment with intravenous (iv) antibiotics within 30 days of entry into study or chronic use of oral antibiotics within 14 days of entry into study.
boolean
C0151317 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
C0009450 (UMLS CUI [3,1])
C0332189 (UMLS CUI [3,2])
C0205164 (UMLS CUI [3,3])
C1708385 (UMLS CUI [4])
C0003232 (UMLS CUI [5,1])
C1522726 (UMLS CUI [5,2])
C0686904 (UMLS CUI [5,3])
C0003232 (UMLS CUI [6,1])
C1527415 (UMLS CUI [6,2])
C0205191 (UMLS CUI [6,3])
Demyelinating disease of central nervous system Pre-existing | Demyelinating disease of central nervous system Onset Recent
Item
preexisting or recent onset of central nervous system (cns) demyelinating disorders.
boolean
C0011302 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C0011302 (UMLS CUI [2,1])
C0332162 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])